Avience Biomedicals
· SME · NSE
Price Band
₹196–208
Lot Size
600 shares
Issue Size
₹30 Cr
Min. Investment
₹1,24,800
Grey Market Premium
Indicative, updates through the day
Estimated listing price: ₹208
Subscription Status
Subscription data will appear once bidding opens.
About Avience Biomedicals
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets. The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the Company also act as distributors and traders of medical equipment. The company's manufacturing unit is situated in Noida, Uttar Pradesh. The company offers a comprehensive range of diagnostic solutions, including: As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees
Issue Objectives
- Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
- Funding the working capital requirements of the Company
- General Corporate Purposes
- Public Issue Expenses
Anchor Investors
Avience Biomedicals IPO raises ₹8.52 crore from anchor investors. Avience Biomedicals IPO Anchor bid date is June 17, 2026.📝 Anchor Investors Letter (PDF)
Reservation
| Category | Shares Offered | % |
|---|---|---|
| QIB | 6,83,400 | 49.83% |
| − Anchor Investor | 4,09,800 | 0% |
| − QIB (Ex. Anchor) | 2,73,600 | 0% |
| NII (HNI) | 2,07,000 | 15.09% |
| − bNII > ₹10L | 1,38,000 | 0% |
| − sNII < ₹10L | 69,000 | 0% |
| Retail | 4,81,200 | 35.08% |
| Market Maker | 82,200 | 0% |
- QIB49.8%
- − Anchor Investor0.0%
- − QIB (Ex. Anchor)0.0%
- NII (HNI)15.1%
- − bNII > ₹10L0.0%
- − sNII < ₹10L0.0%
- Retail35.1%
- Market Maker0.0%
Market Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 1200 | ₹2,49,600 |
| Individual investors (IND) (Max) | 2 | 1200 | ₹2,49,600 |
| S-HNI (Min) | 3 | 1800 | ₹3,74,400 |
| S-HNI (Max) | 8 | 4800 | ₹9,98,400 |
| B-HNI (Min) | 9 | 5400 | ₹11,23,200 |
Financials (₹ Cr)
Valuations
EPS (Pre IPO)
17.94
EPS (Post IPO)
12.56
ROE
22.38%
P/E (Pre IPO)
11.59
P/E (Post IPO)
16.56
Price / Book
2.94
Market Cap
₹114.09 Cr.
Peers Comparison
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Anthem Biosciences Ltd. | 70.62 | ₹3,395.00 Cr |
Contact Details
Avience Biomedicals Ltd. Address
- 1100581800-12-04
- info@avienbio.com
- https://avienbio.com/
Registrar Contact Details
Skyline Financial Services Pvt. Ltd.
- +91 11 4045 0193
- ipo@skylinerta.com
- https://skylinerta.com
- D-153/A, 1st Floor, Okhla Industrial Area Phase-I, New Delhi – 110020
Frequently Asked Questions
Key Dates
- Open Date
- 18 Jun 2026
- Close Date
- 22 Jun 2026
- Listing Date
- 25 Jun 2026
Issue Details
- Registrar
- Skyline Financial
- Lead Manager(s)
- Exchange
- NSE